PepGen (NASDAQ:PEPG - Get Free Report) had its target price dropped by equities researchers at HC Wainwright from $26.00 to $16.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright also issued estimates for PepGen's FY2029 earnings at ($0.21) EPS.
Several other research firms have also weighed in on PEPG. Bank of America lowered shares of PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Monday, December 16th. Wedbush decreased their price target on shares of PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a research report on Friday, November 8th.
Check Out Our Latest Stock Report on PepGen
PepGen Stock Performance
Shares of NASDAQ:PEPG traded down $0.03 during trading on Thursday, reaching $1.26. The company had a trading volume of 469,126 shares, compared to its average volume of 216,015. The firm's fifty day moving average is $3.76 and its 200 day moving average is $7.25. The firm has a market capitalization of $41.01 million, a PE ratio of -0.42 and a beta of 1.54. PepGen has a twelve month low of $1.23 and a twelve month high of $19.30.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.21. Equities analysts predict that PepGen will post -2.73 earnings per share for the current fiscal year.
Institutional Trading of PepGen
Several institutional investors and hedge funds have recently bought and sold shares of PEPG. China Universal Asset Management Co. Ltd. purchased a new position in shares of PepGen in the fourth quarter worth approximately $26,000. Point72 DIFC Ltd purchased a new position in PepGen during the 2nd quarter worth approximately $42,000. Allspring Global Investments Holdings LLC purchased a new position in PepGen during the 3rd quarter worth approximately $95,000. XTX Topco Ltd acquired a new position in PepGen during the third quarter valued at $130,000. Finally, Barclays PLC lifted its stake in PepGen by 318.7% in the 3rd quarter. Barclays PLC now owns 21,971 shares of the company's stock worth $189,000 after acquiring an additional 16,723 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company's stock.
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
See Also
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
